Outcomes on the use of hyperhemolysis prophylaxis in pediatric sickle cell disease patients with history of hyperhemolysis syndrome
Transfusion · 2025-05 · 65 (5) · 1001-1006
DOI: 10.1111/trf.18227 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transfusion, online erschienen am 26.03.2025. Verfasst von HyoJeong Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Center for Cancer and Blood Disorders, Children's National Hospital, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Erythrocyte Transfusion, Hemolysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Background
Hyperhemolysis syndrome (HS) is a rare but severe transfusion‐associated complication seen in patients with sickle cell disease (SCD). The management of HS includes avoidance of post‐hyperhemolysis red blood cell (RBC) transfusion to avoid reoccurrence of HS (recurrent HS). However, complete avoidance of post‐hyperhemolysis RBC transfusion (PHRT) is sometimes not clinically possible, and the standard of care for recurrent HS prophylaxis for patients requiring PHRT has not been established. Case Report We present a retrospective case series of four pediatric patients with SCD and a history of HS requiring PHRT, and describe their HS prophylaxis and outcomes. All patients received HS prophylaxis before transfusion, and three patients received an additional prophylactic regimen post‐transfusion. Three patients were transfused with extended phenotype‐matched RBCs, while one patient received only Rh (D, C/c, E/e) and K antigens matched RBCs. Only one patient did not develop recurrent HS after PHRT. Three patients had documented hemolysis, and two patients met our criteria for recurrent HS, all requiring escalation of care.
Discussion
Even though the patients were treated in the same institution, there was variability in the choice of HS prophylaxis therapy and selection of RBCs, which can be attributed to the lack of guidance on PHRT management. We observed a lack of conclusive evidence in the effectiveness of prophylactic combination immunosuppressive therapy. Our observations suggest caution must be taken when transfusing patients with SCD and a history of HS, as there are no definitive therapies to effectively mitigate the risk of recurrent HS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Center for Cancer and Blood Disorders, Children's National Hospital, Washington, District of Columbia, USA.
- Division of Laboratory and Transfusion Medicine, Children's National Hospital, Washington, District of Columbia, USA.
- Blood Bank/Transfusion Medicine, Texas Children's Hospital, Houston, Texas, USA.
- Departments of Pathology & Immunology, Pediatrics, and Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Department of Anesthesiology and Pain Medicine, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA.
- Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, USA.
ORCID-Profile: HyoJeong Han
Zitieren
APA
Han, H., Hensch, L., Lei, I., Fasipe, T., Teruya, J., & Hui, S. R. (2025). Outcomes on the use of hyperhemolysis prophylaxis in pediatric sickle cell disease patients with history of hyperhemolysis syndrome. Transfusion, 65(5), 1001-1006. https://doi.org/10.1111/trf.18227
Vancouver
Han H, Hensch L, Lei I, Fasipe T, Teruya J, Hui SR. Outcomes on the use of hyperhemolysis prophylaxis in pediatric sickle cell disease patients with history of hyperhemolysis syndrome. Transfusion. 2025;65(5):1001-1006. doi:10.1111/trf.18227
BibTeX
@article{Han2025,
author = {Han, HyoJeong and Hensch, Lisa and Lei, In and Fasipe, Titilope and Teruya, Jun and Hui, Shiu-Ki Rocky},
title = {Outcomes on the use of hyperhemolysis prophylaxis in pediatric sickle cell disease patients with history of hyperhemolysis syndrome},
journal = {Transfusion},
year = {2025},
volume = {65},
number = {5},
pages = {1001--1006},
doi = {10.1111/trf.18227}
}
EUVIMED